| The rationale of indoleamine 2, 3-dioxygenase inhibition for cancer therapy L Brochez, I Chevolet, V Kruse European journal of cancer 76, 167-182, 2017 | 278 | 2017 |
| Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 … M Schreuer, Y Jansen, S Planken, I Chevolet, T Seremet, V Kruse, ... The Lancet Oncology 18 (4), 464-472, 2017 | 205 | 2017 |
| Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours C Van de Wiele, V Kruse, P Smeets, M Sathekge, A Maes European journal of nuclear medicine and molecular imaging 40, 290-301, 2013 | 167 | 2013 |
| Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? P De Bruyn, D Van Gestel, P Ost, V Kruse, L Brochez, H Van Vlierberghe, ... Current opinion in oncology 31 (2), 54-64, 2019 | 79 | 2019 |
| Nephrotoxicity of anticancer drugs–an underestimated problem? N Lameire, V Kruse, S Rottey Acta Clinica Belgica 66 (5), 337-345, 2011 | 79 | 2011 |
| Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review M De Bock, E Hulstaert, V Kruse, L Brochez Case Reports in Dermatology 10 (2), 190-197, 2018 | 70 | 2018 |
| A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV … Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, ... Cancer Immunology, Immunotherapy 69, 2589-2598, 2020 | 57 | 2020 |
| Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure L Pil, I Hoorens, K Vossaert, V Kruse, I Tromme, N Speybroeck, L Brochez, ... Preventive Medicine 93, 177-182, 2016 | 57 | 2016 |
| Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma N Sundahl, T Seremet, J Van Dorpe, B Neyns, L Ferdinande, A Meireson, ... International Journal of Radiation Oncology* Biology* Physics 104 (4), 828-835, 2019 | 49 | 2019 |
| Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports J Marlier, V Cocquyt, L Brochez, S Van Belle, V Kruse Endocrine 47, 878-883, 2014 | 44 | 2014 |
| PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy V Kruse, S Rottey, O De Backer, S Van Belle, V Cocquyt, H Denys Acta Clinica Belgica 66 (1), 2-9, 2011 | 37 | 2011 |
| Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma L Brochez, A Meireson, I Chevolet, N Sundahl, P Ost, V Kruse Nature communications 9 (1), 2921, 2018 | 34 | 2018 |
| Cost-effectiveness and budget effect analysis of a population-based skin cancer screening L Pil, I Hoorens, K Vossaert, V Kruse, I Tromme, N Speybroeck, ... JAMA dermatology 153 (2), 147-153, 2017 | 33 | 2017 |
| Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma N Sundahl, K De Wolf, V Kruse, A Meireson, D Reynders, E Goetghebeur, ... International Journal of Radiation Oncology* Biology* Physics 100 (4), 906-915, 2018 | 32 | 2018 |
| A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response K De Wolf, V Kruse, N Sundahl, M Van Gele, I Chevolet, R Speeckaert, ... Journal of translational medicine 15, 1-6, 2017 | 30 | 2017 |
| Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair … A Meireson, I Chevolet, E Hulstaert, L Ferdinande, P Ost, K Geboes, ... Oncotarget 9 (38), 25216, 2018 | 27 | 2018 |
| Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic: results from the longitudinal ONCOVID survey study EA De Jaeghere, H Kanervo, R Colman, W Schrauwen, P West, ... Cancers 14 (4), 1093, 2022 | 17 | 2022 |
| Serum tumor markers and PET/CT imaging for tumor recurrence detection V Kruse, V Cocquyt, M Borms, A Maes, C Van de Wiele Annals of nuclear medicine 27, 97-104, 2013 | 17 | 2013 |
| Bilateral corneal graft rejection associated with pembrolizumab treatment E Vanhonsebrouck, M Van De Walle, W Lybaert, V Kruse, D Roels Cornea 39 (11), 1436-1438, 2020 | 16 | 2020 |
| Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug–drug interactions V Kruse, A Somers, L Van Bortel, A De Both, S Van Belle, S Rottey Journal of clinical pharmacy and therapeutics 39 (3), 259-265, 2014 | 16 | 2014 |
